공시 • Jan 27
ImpediMed Limited to Report Q2, 2026 Results on Jan 29, 2026 ImpediMed Limited announced that they will report Q2, 2026 results on Jan 29, 2026 공시 • Oct 24
ImpediMed Limited to Report Q1, 2026 Results on Oct 30, 2025 ImpediMed Limited announced that they will report Q1, 2026 results on Oct 30, 2025 공시 • Sep 19
ImpediMed Limited, Annual General Meeting, Nov 18, 2025 ImpediMed Limited, Annual General Meeting, Nov 18, 2025. 공시 • Jul 16
ImpediMed Limited to Report Q4, 2025 Results on Jul 31, 2025 ImpediMed Limited announced that they will report Q4, 2025 results on Jul 31, 2025 공시 • Apr 17
ImpediMed Limited to Report Q3, 2025 Results on Apr 30, 2025 ImpediMed Limited announced that they will report Q3, 2025 results on Apr 30, 2025 공시 • Jan 28
ImpediMed Limited to Report Q2, 2025 Results on Jan 31, 2025 ImpediMed Limited announced that they will report Q2, 2025 results on Jan 31, 2025 공시 • Oct 15
ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024 ImpediMed Limited announced that they will report Q1, 2025 results on Oct 22, 2024 공시 • Sep 27
ImpediMed Limited, Annual General Meeting, Nov 19, 2024 ImpediMed Limited, Annual General Meeting, Nov 19, 2024. 공시 • Aug 23
ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024 ImpediMed Limited announced that they will report fiscal year 2024 results Pre-Market on Aug 29, 2024 공시 • Jun 08
ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director The Board of ImpediMed Limited announced the appointment of Ms Fiona Bones as a non-Executive Director of the Company, effective 07 June 2024. Ms Bones is currently VP of Finance, International Controller at Google and has worked at Google for over 20 years. Ms Bones is a Fellow of the Association of Chartered Certified Accountants, UK and Ireland and brings global experience in finance, corporate governance, and systems transformation. 공시 • Apr 20
ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024 ImpediMed Limited announced that they will report Q3, 2024 results on Apr 30, 2024 공시 • Apr 11
ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting ImpediMed announced that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on April 12, 2024. The study, titled "Timing of Breast Cancer-related Lymphedema Development Over Three Years: Observations from a Large, Prospective Randomized Screening Trial," revealed that patients at risk of developing breast cancer related lymphedema (BRCL) should continue to be monitored for three years following the completion of cancer treatment, as patients could trigger at any time over this period. The results are part of PREVENT, the largest randomized control trial to assess lymphedema prevention, in 1200 women, which monitored progression to BCRL following intervention for BCRL assessed by both bioimpedance spectroscopy (BIS) and a tape measure, demonstrating lower progression to chronic lymphedema with early detection using BIS and intervention versus using tape measure. Lymphedema, a common consequence of cancer treatment, poses significant challenges in healthcare. According to the American Cancer Society 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema, and over 80% of breast cancer patients are at risk. ImpediMed has the only FDA-cleared BIS technology for the clinical assessment of lymphedema. The Company's SOZO® Digital Health Platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with US payors now providing coverage for over 140 million covered lives. The PREVENT trial is a pivotal study and the largest randomized controlled trial to assess lymphedema prevention. The study enrolled 1,200 patients across 10 trial sites in the US and Australia, involving 13 hospitals, including Vanderbilt University, Mayo Clinic and MD Anderson. The trial was conducted over six and a half years and patients were followed for up to three years, with the primary aim to determine if early intervention in patients with subclinical detection of extracellular fluid accumulation via bioimpedance spectroscopy results in a lower rate of lymphedema progression versus the rate when tape measure is used for subclinical detection. The manuscript is published in Lymphatic Research and Biology. The results of the trial demonstrated that patients with early detection with L-Dex™ technology and at-home intervention with compression garments resulted in a 7.9% rate of chronic lymphedema compared to a 19.2% rate of chronic lymphedema using tape measure. The difference is statistically significant (p=0.016) as well as being clinically significant for patients and clinicians. This represents an absolute reduction of 11.3% and relative reduction of 59% in lymphedema progression at three years. 공시 • Jan 23
ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024 ImpediMed Limited announced that they will report first half, 2024 results on Feb 27, 2024 공시 • Oct 24
ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023 ImpediMed Limited announced that they will report Q1, 2024 results on Oct 31, 2023 공시 • Oct 12
ImpediMed Limited, Annual General Meeting, Nov 30, 2023 ImpediMed Limited, Annual General Meeting, Nov 30, 2023, at 10:01 E. Australia Standard Time. 공시 • Sep 27
ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer ImpediMed Limited announced the appointment of Steven Chen, MD, MBA as Chief Medical Officer effective 26 September 2023. Dr. Chen is a board-certified surgical oncologist who brings strong business acumen and extensive leadership experience in cancer care and the healthcare industry. Dr. Chen's previous leadership and experience: Chief Medical Officer of Avelas Biosciences, a clinical stage drug-device company dedicated to improving cancer care. Chief of Breast Surgery, University of California Davis Medical Center. Associate Program Director of the surgical oncology training program at City of Hope National Medical Center, Duarte, California. Past President, American Society of Breast Surgeons (ASBrS). Clinical training at the John Wayne Cancer Institute, the University of Michigan and the Center for Health Care Economics. Over 70 publications and 5,000 citations. The University of California Davis, the City of Hope, and the University of Michigan are members of the National Comprehensive Cancer Network (NCCN®). Most recently, Dr. Chen served as the Chief Medical Officer of Avelas, a clinical stage drug-device company dedicated to improving cancer care. There, he successfully oversaw their lead asset through Investigational New Drug (IND) application and first in human studies through pivotal trials and established the company's clinical strategy to support commercialisation and reimbursement. Previously, Dr. Chen served as the Chief of Breast Surgery at UC Davis Medical Center, followed by a position as an Associate Professor of Surgery and as the Associate Program Director of the surgical oncology training program at City of Hope National Medical Center in Duarte, California. He is a past President of the American Society of Breast Surgeons and serves or served on committees for a number of professional societies including the American Medical Association, the Society of Surgical Oncology, and the American College of Surgeons. Dr. Chen is a practicing surgeon in San Diego, California and the Director of Surgical Oncology at OasisMD. Dr. Chen received his medical degree and completed general surgery and critical care residencies at the University of Michigan, followed by a surgical oncology fellowship at the John Wayne Cancer Institute. Dr. Chen also obtained his master's in business administration at the University of Michigan's Ross School of Business. 공시 • Jul 17
ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023 ImpediMed Limited announced that they will report Q4, 2023 results on Jul 24, 2023 공시 • Jul 06
ImpediMed Limited Appoints Daniel Sharp as Director ImpediMed Limited appointed Mr. Daniel Sharp as director, date of appointment is July 1, 2023. 공시 • Jan 24
ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023 ImpediMed Limited announced that they will report Q2, 2023 results on Jan 30, 2023 
